三叉神経痛(チックドゥールー):パイプラインレビュー2019下半期

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GDATA9120330)
◆英語タイトル:Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2019
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GDATA9120330
◆発行日:2019年11月
◆調査対象地域:グローバル
◆産業分野:製薬及び医療
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[三叉神経痛(チックドゥールー):パイプラインレビュー2019下半期]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Trigeminal Neuralgia (Tic Douloureux) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia (Tic Douloureux) – Pipeline Review, H2 2019, provides an overview of the Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) pipeline landscape.

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Trigeminal Neuralgia (Tic Douloureux) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 4, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Trigeminal Neuralgia (Tic Douloureux) – Overview
Trigeminal Neuralgia (Tic Douloureux) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Trigeminal Neuralgia (Tic Douloureux) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Trigeminal Neuralgia (Tic Douloureux) – Companies Involved in Therapeutics Development
Amgen Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
InMed Pharmaceuticals Inc
Merz Pharma GmbH & Co KgaA
OliPass Corporation
PixarBio Corp
Trigeminal Neuralgia (Tic Douloureux) – Drug Profiles
carbamazepine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTX-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
incobotulinumtoxin A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INM-405 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLP-1002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vixotrigine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Trigeminal Neuralgia (Tic Douloureux) – Dormant Projects
Trigeminal Neuralgia (Tic Douloureux) – Product Development Milestones
Featured News & Press Releases
Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial
Feb 27, 2018: PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat Trigeminal Neuralgia and Post-Surgical Pain
Sep 15, 2016: PixarBio CEO Frank Reynolds to Present NeuroRelease a Non-Addictive Morphine Replacement at the 2016 Aegis Capital Growth Conference in Las Vegas, NV on September 21, 2016
Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch
Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs
Mar 03, 2016: PixarBio’s Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016
Nov 30, 2015: PixarBio’s Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY
Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia
Sep 23, 2014: Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Amgen Inc, H2 2019
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biogen Inc, H2 2019
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2019
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by InMed Pharmaceuticals Inc, H2 2019
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2019
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by OliPass Corporation, H2 2019
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by PixarBio Corp, H2 2019
Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

*** 掲載企業 ***

Amgen Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
InMed Pharmaceuticals Inc
Merz Pharma GmbH & Co KgaA
OliPass Corporation
PixarBio Corp

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • OBDテレマティクスの世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2022)
    "OBD?Telematics is a technology of sending, receiving and storing information via telecommunication devices which can provide details of vehicle for consumer, with a OBD port in vehicles. OBD telematics is mainly composed of three parts: OBD terminal (hardware and plug-in OBD interface), software (m …
  • 自動車用 ブレーキキャリパの世界市場2017-2021:乗用車、商用車
    About Automotive Brake Calipers The brake calipers are basically a clamp or gripping device that squeezes the brake pads or a pair of metal plates (made from various materials like metallic wire, ceramics, asbestos) against the brake rotor to slow down or stop a vehicle. The global automotive brake …
  • 乾式壁用泥土の世界市場
    In this report, the global Drywall Mud market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), m …
  • 世界の水質センサー市場2017
    Water Quality Sensor Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, G …
  • 植物油の世界市場:販売動向2017
    Notes:Sales, means the sales volume of Plant Oil Revenue, means the sales value of Plant Oil This report studies sales (consumption) of Plant Oil in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and …
  • CD 19阻害薬のパイプライン・インサイト2018
    SUMMARY DelveInsight’s, “CD 19 Inhibitors-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the CD 19 Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-cl …
  • 経カテーテル大動脈弁留置術(TAVI)の世界市場
    Transcatheter aortic valve implantation (TAVI), also called as transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure, wherein a diseased aortic valve is replaced with artificial valve through blood vessels. The procedure is designed to treat high-risk patients suf …
  • 世界の住宅用化粧台市場:企業別、地域別、製品種類・用途別分析
    The global Residential Dressing Tables market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2023, growing at a CAGR of XX% between 2017 and 2023. This report offers an overview of the market trends, drivers, and barriers with respect to the Residential Dre …
  • 世界及び中国の超低温フリーザ市場2017
    The 'Global and Chinese Ultra-low Temperature Freezer Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Ultra-low Temperature Freezer industry with a focus on the Chinese market. The report provides key statistics on the market status …
  • 航空補助サービスの世界市場
    Airline Ancillary Services market worldwide is projected to grow by US$119 Billion, driven by a compounded growth of 14. 9%. FFP Miles Sales, one of the segments analyzed and sized in this study, displays the potential to grow at over 17.1%. The shifting dynamics supporting this growth makes it crit …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDATA9120330 )"三叉神経痛(チックドゥールー):パイプラインレビュー2019下半期" (英文:Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2019)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。